Apellis Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Apellis Pharmaceuticals, Inc.

Nov-12	Apellis Announces 5-Year GALE Data Showing SYFOVRE (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years APLS GlobeNewswire
Nov-05	Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference APLS GlobeNewswire
Oct-30	Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results APLS GlobeNewswire
Oct-20	New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week APLS GlobeNewswire
Oct-16	Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results APLS GlobeNewswire
Aug-27	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences APLS GlobeNewswire
Jul-31	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results APLS GlobeNewswire
Jul-28	FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older APLS GlobeNewswire
Jul-24	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results APLS GlobeNewswire
Jul-15	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting APLS GlobeNewswire
Jul-01	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan) APLS GlobeNewswire
Jun-04	Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference APLS GlobeNewswire
May-07	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results APLS GlobeNewswire
May-06	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences APLS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.